Gettinger S, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Abstract OA14.04. WCLC 7-10 sept. 2019, Barcelona, Spanje.
Congressen IGCA en ESDE: beide geslaagd, en ook verbinding
jul 2025 | Maag-darm-leveroncologie